t
Genflow Biosciences Plc announced on July 19, 2022, that its CEO and director, Eric Leire, purchased Ordinary Shares. The Company was notified on July 15 and 18, 2022, that Mr. Leire acquired 308,999 Ordinary Shares at a weighted average price of 3.03p per share. This purchase resulted in his total shareholding becoming 120,308,999 Ordinary Shares, representing 41.13% of the Company's total voting rights.
| Date | 19 Jul 2022 |
| Time | 07:00:08 |
| Category | Director/PDMR dealings |
| ID | 8872S |
19 July 2022
Genflow Biosciences Plc
("Genflow" or "the Company")
Company Share Purchase by CEO
Genflow Biosciences (LSE: GENF), a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age,
announces that it was notified on 15 July 2022 and 18 July 2022, that Eric Leire, a director of the Company, purchased the following Ordinary Shares:
|
PDMR / Person closely associated |
Total Number of Ordinary Shares Purchased |
Weighted Average Price per Ordinary Share |
Resultant Shareholding |
Percentage Of The Total Voting Rights of the Company |
|
Eric Leire |
308,999 |
3.03p |
120,308,999 |
41.13 |
Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link: https://genflowbio.com/investors/news-releases/
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
For further information please contact:
|
Genflow Biosciences |
|
|
Dr Eric Leire Chief Executive |
via Tancredi +44 203 434 2330 |
|
Clear Capital |
|
|
Corporate Broker
Jonathan Critchley Keith Swann |
+44 203 869 6086
+44 203 897 0981 |
|
Tancredi Intelligent Communication Media Relations |
|
|
Salamander Davoudi Helen Humphrey Benedetta Negri da Oleggio |
+44 7957 549 906 +44 7449 226 720 +44 7838 029 970 |
About Genflow Biosciences
Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.
Its mission is to increase our understanding of the factors that control and impact lifespan. Genflow researchs, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.
To learn more visit www.genflowbio.com